...Welcome To The Resverlogix HUB On AGORACOM!

**Apabetalone (RVX-208) Currently Being Tested in a Phase 3 BETonMACE Cardiovascular Outcomes Trial (now fully enrolled) and Will Soon Begin Phase 2 Kidney Dialysis and Fabry Disease Trials**

Free
AGORACOM NEWS FLASH

BREAKING:Monarques Gold Confirms Pit Constrained Resource on its Mckenzie Break

  • The mineral resource estimate for McKenzie Break was prepared for two scenarios:
    • Scenario 1: A pit constrained Indicated resource of 48,133 ounces and Inferred resource of 14,897 ounces, and an underground Indicated resource of 53,448 ounces and Inferred resource of 49,130 ounces, for a total of 165,608 ounces of gold.
    • Scenario 2: An underground Indicated resource of 85,059 ounces and Inferred resource of 58,373 ounces, for a total of 143,432 ounces of gold.
  • Monarques Gold now has a combined measured and indicated resource of more than 3 million ounces of gold

Monarquesgold hub large

Hub On AGORACOM / Read Release

Message: Another application/indicati... for the compound libraries

Selective BET bromodomain inhibition as an antifungal therapeutic strategy

https://www.ncbi.nlm.nih.gov/pubmed/28516956

Candida albicans is a major human fungal pathogen. Resverlogix and Zenith have thousands of compounds in their small molecule libraries. Several of these may be able to discriminate CaBdf1 from human BET bromodomain proteins.

"These findings establish BET inhibition as a promising antifungal therapeutic strategy and identify Bdf1 as an antifungal drug target that can be selectively inhibited without antagonizing human BET function."

"In summary, CaBdf1 and human BET BDs have distinct BETi-binding activity, supporting the feasibility of targeting CaBdf1 BDs with highly selective small-molecule inhibitors."

BDAZ

Share
New Message
Please login to post a reply